Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Barbara Ann Karmanos Cancer Institute Identifier:
First received: April 6, 2000
Last updated: April 3, 2013
Last verified: April 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2005
  Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
Ibrahim D, Hussain M, LoRusso P, et al.: Rebeccamycin analog (BMY-27557-14) in renal cell cancer (RCC): preliminary results of a phase II trial. [Abstract] Proceedings of the American Society of Clinical Oncology A-2373, 2001.